The Freakonomics Radio Book Club 32. Why Has There Been So Little Progress on Alzheimer’s Disease?
Apr 17, 2026
Matthew Schrag, an associate professor studying vascular contributors to dementia and a research-integrity whistleblower. Charles Piller, an investigative journalist who exposes scientific fraud in biomedical research. They discuss suspected data manipulation that warped Alzheimer’s research, contested amyloid-focused theories, forensic evidence of altered images, institutional slow responses, and alternative paths like brain waste clearance and vascular health.
AI Snips
Chapters
Books
Transcript
Episode notes
Amyloid Hypothesis Became The Dominant Dogma
- The amyloid cascade hypothesis made beta amyloid the primary target for decades of Alzheimer's research and drug development.
- Matthew Schrag explains the field treated plaques as the first domino, driving billions into anti-amyloid trials that may oversimplify a complex disease.
Whistleblowers Brought Schrag Into The Cassava Case
- Schrag was recruited by whistleblowers and an attorney to analyze image data behind Cassava Sciences' experimental drug simufilam.
- He found apparent image retouching and copy-paste manipulations that altered quantitative measurements and alerted the FDA and NIH.
Seminal 2006 Paper Later Found Questionable
- A highly cited 2006 Nature paper by Lesné and Ashe promoted a specific amyloid oligomer as the toxic 'silver bullet' in Alzheimer's.
- Charles Piller and Schrag's image forensics later found manipulated Western blots that undermined the paper's credibility.
